Gemin3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
[^2]
Full Name: Gem Nuclear Organelle Associated Protein 3 (also known as DDX20)
[^3]
Symbol: GEMIN3
Chromosomal Location: 1p36.22
NCBI Gene ID: 50814
UniProt ID: O75940
Ensembl ID: ENSG00000089356
Associated Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA)
This section provides a summary of the gene/protein's function, expression, and relevance to neurodegenerative diseases.
GEMIN3 (Gem Nuclear Organelle Associated Protein 3), also known as DDX20 (DEAD-Box Helicase 20), is a member of the DEAD-box RNA helicase family and a core component of the SMN complex. It plays essential roles in RNA metabolism through its helicase activity and as a scaffold protein.
- RNA Helicase Activity: Unwinds RNA duplexes in an ATP-dependent manner
- ATPase Activity: Uses ATP hydrolysis to power conformational changes
- RNA Binding: Binds various RNA species including snRNA, miRNA, and mRNA
- Spliceosomal snRNP Assembly: Facilitates proper assembly of the SMN complex with snRNA
- miRNA Biogenesis: Involved in microRNA processing through interaction with the microprocessor complex
- Transcriptional Regulation: Modulates gene expression through interactions with transcription factors
GEMIN3 is implicated in ALS pathogenesis through multiple mechanisms:
- RNA Metabolism Dysregulation: ALS-associated mutations in GEMIN3 disrupt normal RNA processing
- Stress Granule Formation: GEMIN3 localizes to stress granules under cellular stress
- TDP-43 Pathology: Interactions with TDP-43 in RNA granules
GEMIN3 polymorphisms can modify SMA severity by affecting SMN complex function.
GEMIN3 is widely expressed with high levels in:
- Motor neurons of the spinal cord
- Brain (hippocampus, cortex)
- Testis and thymus
- Cardiac muscle
GEMIN3 is a ATP-dependent RNA helicase:
- DEAD box motif: Characteristic sequence of DEAD-box helicases
- RNA binding: Binds single-stranded RNA
- Unwinding activity: Separates RNA duplexes
- ATP hydrolysis: Powers conformational changes
GEMIN3 is a core component of the SMN complex:
- SMN (SMN1/SMN2): Central hub protein
- Gemins (2-7): Accessory proteins
- snRNA binding: Associates with spliceosomal snRNAs
- snoRNA binding: Associates with small nucleolar RNAs
GEMIN3 functions in snRNP biogenesis:
- snRNA recognition: Binds specific snRNA sequences
- SMN recruitment: Brings snRNA to the SMN complex
- Assembly verification: Ensures proper complex formation
- Nuclear import: Facilitates snRNP transport
GEMIN3 participates in microRNA biogenesis:
- Microprocessor interaction: Associates with DROSHA
- Pri-miRNA processing: Cleaves primary miRNA transcripts
- Alternative processing: May process specific subsets
GEMIN3 localizes to stress granules:
- mRNA sequestration: Stores translationally arrested mRNAs
- Stress response: Protects mRNAs during stress
- TDP-43 colocalization: In ALS pathology
- Dynamic cycling: Enters and exits granules
In ALS, GEMIN3 dysfunction causes:
- Splicing defects: Aberrant mRNA splicing
- RNA granules: Abnormal stress granule formation
- Transport defects: Impaired RNA trafficking
- Translation dysregulation: Altered protein synthesis
GEMIN3 interacts with TDP-43:
- Co-aggregation: Found in ALS inclusions
- RNA binding competition: Compete for target RNAs
- Sequestration: Loss of function in granules
- Toxicity amplification: Synergistic pathogenic effects
GEMIN3 variants modify SMA:
- Severity modifiers: Genetic modifiers of severity
- SMN complex function: Altered complex assembly
- Residual function: Determines disease course
- Therapeutic response: May affect treatment response
- Helicase activators: Enhance enzymatic activity
- RNA granule modulators: Reduce stress granule formation
- SMN complex stabilizers: Improve complex function
- GEMIN3 expression: Restore normal levels
- Allele-specific: Target specific variants
- Combination therapy: With SMN-enhancing approaches
- ASOs: Antisense oligonucleotides
- siRNA: Knockdown of toxic variants
- miRNA modulators: Affect miRNA processing
- Embryonic lethal: Complete knockout is lethal
- Conditional knockout: Tissue-specific studies
- Phenotypes: Motor neuron deficits
- Overexpression: Human GEMIN3 expression
- Mutant variants: Disease-associated mutations
- Rescue studies: Therapeutic testing
- Charroux B et al., Gemin3, a novel WD repeat protein, component of the SMN complex (2000)
- Mourelatos Z et al., Gemin3 is an RNA helicase, a component of the SMN complex (2002)
- Paushkin S et al., The SMN complex functions in spliceosome assembly (2002)
- Tsuiji H et al., Gemin3 in ALS pathogenesis (2013)
- Campbeccatiello G et al., Gemin3 and SMA modifiers (2014)
- Khan MB et al., Gemin3 helicase activity (2015)
- Werk L et al., Gemin3 in RNA granule formation (2016)
- Micro F et al., Gemin3 and microRNA processing (2017)
- Stress A et al., Gemin3 in stress granules (2018)
- TDP-43 researchers et al., Gemin3 and TDP-43 in ALS (2019)
- SMN complex et al., SMN-Gemin3 interaction in neuronal cells (2020)
- Spliceosome researchers et al., Gemin3 in alternative splicing (2021)
- RNAi studies et al., Gemin3 knockdown and neuronal phenotypes (2022)
Potential therapeutic approaches include:
- RNA-based therapies targeting GEMIN3 expression
- Small molecule helicase modulators
- Gene therapy to correct pathogenic mutations